Skip to main content

DCVC Bio — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

56
Companies
$2.5B
Total invested
$61.8M
Avg. check
30
Industries
Biotechnology 18Therapeutics 12Medical 9Life Science 5Manufacturing 4Biopharma 3+24 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 124 of 56
Novome Biotechnologies
September 2022

Novome Biotechnologies is a biotechnology company focused on engineering defined activities into the human.

Biopharma · South San Francisco$43.5M Series B
Verdant Robotics, Inc.
August 2022

Verdant builds AI-powered Smart Sprayers that weed, thin, fertilize & deliver nutrients at millimeter level.

Agriculture · Hayward$46.5M Series A
Plexium
August 2025

Plexium develops a targeted protein degradation platform to find new therapies for cancer and other diseases.

Biotechnology · San Diego$60.1M Series C
Alchemab Therapeutics
July 2026

Alchemab Therapeutics is developing protective antibodies designed to keep people free of hard-to-treat diseases.

Biotechnology · London$33.6M Series A
MycoWorks
July 2024

MycoWorks is a biotechnology company that offers non-plastic and non-animal materials to the market.

Biotechnology · EmeryvilleSeries D
Estes Energy
July 2025

Estes Energy is a California-based startup developing advanced, U.S.-made, chemistry-agnostic battery packs for mobility and industry.

Chemical · San Francisco$11.0M Seed
Auron Therapeutics
July 2025

Auron aims to cure cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells.

Biotechnology · NewtonVenture - Series Unknown
Stemson Therapeutics
July 2021

Stemson Therapeutics is a pre-clinical stage cell therapy company.

Biotechnology · San Diego$15.0M Series A
Sabanto
July 2026

Sabanto provides a Farming-as-a-Service tool that transforms existing tractors into fully autonomous machines.

Agriculture · Chicago$17.0M Series B
Frontier Medicines
June 2024

Frontier Medicines is a biopharmaceutical company that develops a chemoproteomics platform to accelerate the development of medicines.

Biopharma · San Francisco$20.0M Series C
SyntaxBio
June 2026

Syntax Bio is a biotechnology company that develops a cell programming platform to control stem cell differentiation for research.

Biotechnology · Chicago$14.4M Series A
Latus Bio
May 2026

Latus Bio develops gene therapy candidates, particularly for treating central nervous system (CNS) disorders using screened AAV capsids.

Biopharma · Philadelphia$43.0M Series A
AbCellera
May 2023

AbCellera is an antibody discovery and development company that develops antibody therapeutics to improve patient outcomes.

Biotechnology · Vancouver$515.8M Grant
Sidewinder Therapeutics
April 2026

Sidewinder Therapeutics is a biotechnology company that offers life-saving therapies for cancer and rare diseases.

Biotechnology · San Diego$137.0M Series B
Grove Biopharma
April 2025

Grove Biopharma is a biotechnology company offering a materials science solution to peptide therapeutic challenges.

Analytics · Chicago$30.0M Series A
Creyon Bio
March 2022

Reinventing drug development from the ground up to make safe, effective oligonucleotide-based medicines possible on demand.

Biotechnology · San Diego$40.0M Series A
Ascend Gene & Cell Therapies
March 2023

Ascend Gene & Cell Therapies is a model for gene and cell therapy manufacturing.

Biotechnology · Potters Bar$65.9M Series A
Empirico
March 2023

Empirico is a developer of an insights platform designed to turn biological insights from human genetics into new medicines.

Biotechnology · San Diego$45.2M Series B
AgZen
March 2026

AgZen develops pesticide sprays stick to plants which reduces pollution and helps farmers save.

Agriculture · Somerville$10.0M Series B
Chroma Medicine
February 2023

Chroma Medicine is a biotechnology company that develops genetic medicines for the treatment of genetic disorders.

Biotechnology · Cambridge$135.0M Series B
Solu Therapeutics
April 2025

Solu Therapeutics Platform Company that develops antibody-based medicines using a degradable warhead.

Biotechnology · Boston$41.0M Series A
Newleos Therapeutics
February 2025

Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines.

Biotechnology · Boston$93.5M Series A
Valar Labs
May 2024

Valar Labs offers assistance services for cancer treatment through Artificial Intelligence.

Artificial Intelligence (AI) · Palo Alto$22.0M Series A
Unlearn.AI
February 2024

Unlearn.AI combines AI, digital twins, and novel statistical methods to enable smaller, more efficient clinical trials.

Artificial Intelligence (AI) · San Francisco$50.0M Series C

Where DCVC Bio invests

Biotechnology18
Therapeutics12
Medical9
Life Science5
Manufacturing4
Biopharma3

About DCVC Bio's portfolio

How many companies has DCVC Bio invested in?

DCVC Bio has invested in 56 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does DCVC Bio invest in?

DCVC Bio's top investment sectors include Biotechnology, Therapeutics, Medical, Life Science, Manufacturing. The firm invests across 30 different industry categories.

What is DCVC Bio's largest investment?

Among tracked funding rounds, AbCellera received $515.8M in a Grant round. DCVC Bio's total known invested capital is $2.5B.

What is the average investment size for DCVC Bio?

DCVC Bio's average investment size is $61.8M across its portfolio of 56 companies.

What are DCVC Bio's most recent investments?

Recent DCVC Bio portfolio additions include Novome Biotechnologies, Verdant Robotics, Inc., Plexium, Alchemab Therapeutics, MycoWorks. These companies were founded in 2020 or later.

Reach the founders behind these 56 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →